MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

Rajeshkumar, N V

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research May 2011 - 2799-806 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1557-3265

10.1158/1078-0432.CCR-10-2580 doi


Animals
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carcinoma, Pancreatic Ductal--drug therapy
Cell Cycle Proteins--antagonists & inhibitors
Cell Line, Tumor
Deoxycytidine--administration & dosage
Disease Progression
Drug Synergism
Female
Genes, p53
Humans
Mice
Mice, Nude
Mutation--physiology
Neoplasms--drug therapy
Nuclear Proteins--antagonists & inhibitors
Pancreatic Neoplasms--drug therapy
Protein Kinase Inhibitors--administration & dosage
Protein-Tyrosine Kinases--antagonists & inhibitors
Pyrazoles--administration & dosage
Pyrimidines--administration & dosage
Pyrimidinones
Tumor Burden--drug effects
Xenograft Model Antitumor Assays
Gemcitabine